Zepbound led to an average weight loss of 20.2 percent compared to Wegovy's 13.7 percent. We talked with healthcare experts to understand the study’s findings, what sets these drugs apart and ...

People taking Eli Lilly's obesity drug, Zepbound, lost nearly 50% more weight than those using rival Novo Nordisk's Wegovy in the first head-to-head study of the blockbuster medications. Clinical ...

Zepbound brought in sales of $176 million through Dec. 31, according to Lilly. Novo Nordisk, the Danish manufacturer of Ozempic and Wegovy, also has raked in billions from the sale of the weight ...

Zepbound, a weight loss drug by Eli Lily, received FDA approval. How the tirzepatide-containing drug works, potential side effects, and insurance coverage.

Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging. Reduced monthly costs for uninsured patients still amount to around $500.

Tirzepatide is the active ingredient in Zepbound and in Eli Lilly's diabetes counterpart Mounjaro, which are part of a class of highly popular medications called GLP-1s. She said compounded ...

Zepbound is a weight loss drug that was approved by the Federal Drug Administration on Wednesday. It joins Ozempic and Wegovy as potential tools people seeking to manage their weight can turn to.

Zepbound is available for those with a BMI of 25 or higher. Those with a BMI of 25 to 29 are considered overweight and will need a comorbidity — such as high blood pressure, high cholesterol or ...

Eli Lilly' s blockbuster weight loss drug Zepbound and diabetes treatment Mounjaro posted weaker-than-expected sales for the third quarter, even as supply of both medicines has largely recovered ...

Zepbound generated $4.9 billion in global sales last year. Wegovy brought in nearly $8.8 billion (58.2 billlion Danish kroner). Access and affordability have limited wider use of the drugs.

Zepbound generated $4.9 billion in global sales last year. Wegovy brought in nearly $8.8 billion (58.2 billlion Danish kroner). Access and affordability have limited wider use of the drugs.